Presentation is loading. Please wait.

Presentation is loading. Please wait.

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.

Similar presentations


Presentation on theme: "CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma."— Presentation transcript:

1 CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma of the colon or rectum Presented By Alan Venook at 2014 ASCO Annual Meeting

2 Slide 2 Presented By Alan Venook at 2014 ASCO Annual Meeting

3 CALGB/SWOG 80405: FINAL DESIGN Presented By Alan Venook at 2014 ASCO Annual Meeting

4 COLORECTAL CANCER IN 2004 IS THERE AN OPTIMAL 1ST LINE TREATMENT ? Presented By Alan Venook at 2014 ASCO Annual Meeting

5 2004: A lot can happen in 10 years Presented By Alan Venook at 2014 ASCO Annual Meeting

6 CALGB / SWOG 80405: WHY DID IT TAKE TEN YEARS? Presented By Alan Venook at 2014 ASCO Annual Meeting

7 CALGB/SWOG 80405: Eligibility Criteria Presented By Alan Venook at 2014 ASCO Annual Meeting

8 CALGB/SWOG 80405: Endpoints Presented By Alan Venook at 2014 ASCO Annual Meeting

9 CALGB/SWOG 80405: Statistics Presented By Alan Venook at 2014 ASCO Annual Meeting

10 CALGB/SWOG 80405: Statistics Presented By Alan Venook at 2014 ASCO Annual Meeting

11 Slide 11 Presented By Alan Venook at 2014 ASCO Annual Meeting

12 Slide 12 Presented By Alan Venook at 2014 ASCO Annual Meeting

13 CALGB/SWOG 80405: Overall Survival Presented By Alan Venook at 2014 ASCO Annual Meeting

14 CALGB/SWOG 80405: Progression-Free Survival (Investigator Determined) Presented By Alan Venook at 2014 ASCO Annual Meeting

15 Slide 15 Presented By Alan Venook at 2014 ASCO Annual Meeting

16 CALGB/SWOG 80405: Overall Survival FOLFOX Treated Presented By Alan Venook at 2014 ASCO Annual Meeting

17 CALGB/SWOG 80405: Overall Survival FOLFIRI Treated Presented By Alan Venook at 2014 ASCO Annual Meeting

18 Patients Rendered Disease-Free Overall Survival Presented By Alan Venook at 2014 ASCO Annual Meeting

19 Grade 3-4 Toxicities Presented By Alan Venook at 2014 ASCO Annual Meeting

20 Slide 20 Presented By Alan Venook at 2014 ASCO Annual Meeting

21 80405: Data Pending Presented By Alan Venook at 2014 ASCO Annual Meeting

22 Quality of Life and Symptoms Presented By Alan Venook at 2014 ASCO Annual Meeting

23 Slide 23 Presented By Alan Venook at 2014 ASCO Annual Meeting

24 “Expanded RAS” Presented By Alan Venook at 2014 ASCO Annual Meeting

25 Correlative Studies Tumor / Plasma / Serum > 44000 samples Presented By Alan Venook at 2014 ASCO Annual Meeting

26 80405: Upcoming Presentations Presented By Alan Venook at 2014 ASCO Annual Meeting

27 CALGB/SWOG 80405: Conclusions Presented By Alan Venook at 2014 ASCO Annual Meeting

28 CALGB/SWOG 80405: Conclusions Presented By Alan Venook at 2014 ASCO Annual Meeting

29 CALGB/SWOG 80405: Conclusions Presented By Alan Venook at 2014 ASCO Annual Meeting

30 Slide 30 Presented By Alan Venook at 2014 ASCO Annual Meeting

31 TAKE HOME MESSAGE Presented By Alan Venook at 2014 ASCO Annual Meeting

32 Value of publicly funded clinical research Presented By Alan Venook at 2014 ASCO Annual Meeting

33 ACKNOWLEDGEMENTS / THANKS Collaborators Presented By Alan Venook at 2014 ASCO Annual Meeting

34 ACKNOWLEDGEMENT / THANK YOU Presented By Alan Venook at 2014 ASCO Annual Meeting

35 Slide 35 Presented By Alan Venook at 2014 ASCO Annual Meeting

36 Slide 36 Presented By Alan Venook at 2014 ASCO Annual Meeting


Download ppt "CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma."

Similar presentations


Ads by Google